Adicet Bio, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Adicet Bio, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($26.86M) | Nov 5, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($31.22M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($31.22M) | Aug 7, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($28.21M) | Aug 7, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($28.21M) | Nov 5, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($28.21M) | May 6, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($30.48M) | Nov 5, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($29.90M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($29.90M) | Aug 7, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($28.02M) | Nov 5, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($28.02M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($28.02M) | May 6, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($49.89M) | Nov 6, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($32.40M) | Nov 6, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($32.40M) | Aug 13, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($30.88M) | Nov 6, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($30.88M) | Aug 13, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($30.88M) | May 14, 2024 |
| Q1 | 2023 | Dec 31, 2022 | $4.62M | May 9, 2023 |
| Q3 | 2023 | Sep 30, 2022 | ($22.00M) | Nov 8, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($27.95M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($32.39M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($29.89M) | May 6, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($33.15M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($32.85M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($30.87M) | May 6, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($52.26M) | Nov 6, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($34.89M) | Aug 13, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($33.32M) | May 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($22.99M) | Nov 8, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($22.71M) | Aug 9, 2023 |
| Q1 | 2023 | Mar 31, 2022 | $4.71M | May 9, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($13.71M) | Nov 8, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($10.83M) | Aug 10, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($21.35M) | May 12, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($13.66M) | Nov 10, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($8.63M) | Aug 12, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($7.56M) | May 17, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($15.23M) | Nov 5, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($19.17M) | Jul 30, 2020 |